Second Sight announced in a press release the publication of positive results from a long-term clinical trial of the Argus II Retinal Prosthesis System. According to the press release, the five-year trial included 30 subjects who were blind due to retinitis pigmentosa (RP). The results, which will be published in Ophthalmology, indicate that the Argus II device provided improved visual function that was sustained over the course of the trial. The study further reported improved patient well-being and an acceptable safety profile. Will McGuire, President and CEO of Second Sight, said:
“We are excited to see that the substantial visual improvement gained from the Argus II endures over five years – promising news for patients blinded by RP, as well as for our company’s continued efforts to restore vision.”
The Argus II Retinal Prosthesis System assists wearers with RP-related blindness by capturing images using an eyeglass-mounted camera, converting the images to electrical pulses, and transmitting the electrical pulses to the retinal surface. The Argus II system received FDA approval in February 2013, and according to the press release a 2014 study supported the device’s long-term cost effectiveness.